CyDex Pharmaceuticals Announces CAPTISOL(R) Technology Used in Recently Approved Cosolvent-Free Formulation of Amiodarone IV

Published: Jan 05, 2009

LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals’ NEXTERONE®, which recently received new drug application (NDA) approval from the U.S. Food and Drug Administration (FDA), is based on the patent-protected CyDex CAPTISOL® technology platform. NEXTERONE is the first CyDex proprietary product to achieve the milestone of NDA approval.

Back to news